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Membrane-active peptides have been extensively studied to probe protein–membrane
interactions, to act as antimicrobial agents and cell-penetrating peptides (CPPs) for the
delivery of therapeutic agents to cells. Hundreds of membrane-active sequences acting
as CPPs have now been described including bioportides that serve as single entity modi-
fiers of cell physiology at the intracellular level. Translation of promising CPPs in pre-clin-
ical studies have, however, been disappointing as only few identified delivery systems
have progressed to clinical trials. To search for novel membrane-active peptides a
sequence from the EGFR juxtamembrane region was identified (named EJP18), synthe-
sised, and examined in its L- and D-form for its ability to mediate the delivery of a small
fluorophore and whole proteins to cancer cell lines. Initial studies identified the peptide as
being highly membrane-active causing extensive and rapid plasma membrane reorgan-
isation, blebbing, and toxicity. At lower, non-toxic concentrations the peptides outper-
formed the well-characterised CPP octaarginine in cellular delivery capacity for a
fluorophore or proteins that were associated with the peptide covalently or via ionic inter-
actions. EJP18 thus represents a novel membrane-active peptide that may be used as a
naturally derived model for biophysical protein–membrane interactions or for delivery of
cargo into cells for therapeutic or diagnostic applications.
Introduction
The term cell-penetrating peptide (CPP) or protein transduction domain relates to short peptide
sequences, usually less than 30 amino acid residues, that have the capacity to deliver themselves and
cargo of various forms and sizes to the inside of cells. Since the original discoveries of now well-
characterised protein derived CPPs such as Tat and penetratin [1], and synthetic variants such as
octaarginine (R8) there has been considerable effort in exploiting their translocating activities for
therapeutic and diagnostic purposes [2]. In in vitro models these CPPs, and several others, have
shown the impressive capacity to deliver a range of readout and therapeutic cargo to many cell types,
including small molecule drugs or fluorophores and much larger molecules such as nucleotides, pep-
tides, proteins, and nanoparticles [3,4]. Translation of this to effective in vivo delivery has, however,
been disappointing and the search continues for novel CPPs or strategic modifications of existing
CPPs to improve their delivery performance. CPPs can generally be categorised into three major
classes: (i) cationic, such as Tat derived peptides and polyarginines [5], (ii) amphipathic, in which the
alterations between cationic and hydrophobic residues give rise to α-helical structures upon membrane
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interactions [6], e.g. MAP and transportan, and (iii) hydrophobic, such as the PFVYLI sequence [7] and syn-
thetic variants [8]. Additionally, anionic CPPs have also been shown to deliver fluorophores into a range of cell
lines [9–11]. It should be noted that in many cases a finite window exists between a CPPs ability to translocate
in the absence of cell toxicity and its more global effects on cells in the form of induction of plasma membrane
porosity or other indirect effects [12–14].
Cancer cells which overexpress EGFR (ErbB1) have increased activation of downstream signalling pathways
driving cell proliferation, survival, angiogenesis, and metastasis [15]. This receptor tyrosine kinase has been tar-
geted using antibodies, antibody-drug conjugates, small molecule drugs, and protein–protein interaction inhi-
biting peptides that act on the phosphorylated cytosolic portion of the receptor to influence its ability to signal
[16]. These peptides are often synthesised as CPP chimeras to allow plasma membrane translocation and access
of the targeting sequence to the receptor. One example is TE-64562 containing the HIV-Tat49–58 peptide
sequence (bold) linked to an 18 residue sequence derived from the juxtamembrane ( JM) domain of EGFR
(RKKRRQRRRGRRRHIVRKRTLRRLLQER) [17]. This EGFR domain region (corresponding to amino acids
645–682 (RRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRI) lies immediately downstream of the trans-
membrane region and harbours a tripartite nuclear localisation sequence (NLS) (RRRHIVRKRTLRR, amino
acids 645–657) containing three clusters of basic amino acids (bold) [18]. The JM region itself regulates recep-
tor dimerisation, signalling, and endocytosis [19,20]. Our further scrutiny of the EGFR JM region identified
three upstream N-terminal amino acids LFM (642–645) that would introduce hydrophobicity to this terminus.
Along with a double leucine (658–659) hydrophobic C-terminus, these hydrophobic termini would flank the
tripartite NLS and produce the 18 amino acid sequence 642-LFMRRRHIVRKRTLRRLL-659. As an unmodified
peptide, it would have a mass of 2421.0 Dalton, an isoelectric point of 12.88, and a net charge of 8.1 at pH 7.0
(pepcalc.com). Our interest in this sequence stems from the fact that in this natural sequence located at the
cytosolic/plasma membrane interface, the cationic (hydrophilic) residues are spaced between hydrophobic resi-
dues. Based on other CPP sequences and findings that terminal hydrophobicity of CPPs influences peptide–cell
interactions [21,22], it was hypothesised that this peptide, that we term EGFR Juxtamembrane Peptide-18
(EJP18) may have CPP activity and EGFR dependant cytotoxicity when added to cells and thus act as a biopor-
tide [23].
In this study, we demonstrate that EJP18 can be classified as a novel CPP having the capacity to effectively
deliver a fluorophore and proteins to cells whether as non-covalent complexes or covalently in the frame after
expression in Escherichia coli. At higher concentrations, the membrane activities of L-EJP18 and especially
D-EJP18 were pronounced, manifested as rapid and extensive plasma membrane blebbing and damage in cells
independent of their EGFR expression. Analysis of the JM regions of other receptor tyrosine kinases in the
human genome reveals that several may contain interesting sequences with cell-penetrating capacity.
Materials and methods
Chemicals and reagents
All peptides used in this study (Table 1), were purchased from EZBiolab (Parsippany, NJ, U.S.A.). Cell culture
media, serum, trypsin, Hoechst 33342 (#H3570), bovine serum albumin (BSA)-Alexa647 (#A13100),
BSA-Alexa488 (#A34785), dextran-Alexa488 (#D22910) were purchased from Fisher Scientific (Loughborough, U.
K.). Agarose, Mini-PROTEAN® TGXTM gels 10% (#456-1033), Clarity Western Enhanced Chemiluminescence
substrate, sodium dodecyl Sulfate, precision plus protein dual colour standards were obtained from Bio-Rad
(Watford, U.K.). Horseradish peroxidase (HRP) conjugated mouse anti-β-tubulin (#AB21058) was purchased
from Abcam (Cambridge, U.K.). Rabbit anti-EGFR (#HPA018530) was from Sigma (Gillingham, U.K.) and goat
anti-rabbit HRP (#32460) was from Fisher Scientific. DRAQ7TM (#DR71000) was from Biostatus (Leicestershire,
U.K.) and CellTiter-Blue® viability reagent was purchased from Promega (Southampton, U.K.).
DMEM, RPMI 1640, 0.05% Trypsin-EDTA were all obtained from Life Technologies (Fisher Scientific).
Phosphate-buffered saline (PBS) was made in house and buffered to pH7.4.
All peptides and protein conjugates used in this study are described in Table 1.
eGFP-CPP conjugates
Plasmids pEV eGFP and pEV eGFP-R8 were described previously [24]. To construct plasmid pEV eGFP-EJP18,
the vector for the plasmid was PCR-amplified from pEV eGFP with primers TAGGAATTCAAGCTTAAGCT
GAGCAATAACTAGC and CCATGTGGTGGTGGTGGTGGTGCATATGTATATCTC, the insert for the
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plasmid was PCR- amplified from pEV eGFP with primers CCACCACCACCACCACATGGTGAGCAAGGGCG
AG and AGCTTAAGCTTGAATTCCTACAGCAGGCGGCGCAGGGTGCGTTTGCGCACAATATGGCGGCG
GCGCATAAACAGCTTGTACAGCTCGTCCATGCCGAG. The two PCR fragments were joined together by
Gibson assembly to afford the desired plasmid. The nucleotide sequences encoding eGFP-EJP18 and the corre-
sponding amino acid sequence are shown in the Supplementary Information. Characterisation data can be
found in Supplementary Figures S1 and S2. Recombinant eGFP, eGFP-R8, and eGFP-EJP18 proteins were
expressed and purified as previously described [25].
Cell culture
HeLa, human cervical carcinoma, cells (ATCC, Middlesex, U.K.), MCF-7 and MDA-MB-231, both breast
cancer cells (ATCC), and A431 epidermal cancer cells (School of Dentistry, Cardiff University) were main-
tained in a humidified 5% CO2 37°C incubator in DMEM supplemented with 10% foetal bovine serum (FBS).
Human acute myeloid leukaemia KG1a cells (ECACC, Porton Down, U.K.) were maintained as a suspension in
RPMI 1640 medium supplemented with 10% FBS. Herein medium supplemented with FBS are termed com-
plete media (CM). Each adherent cell line was sub-cultured after 3–5 days of growth, at 70%–90% confluency.
KG1a cells were passaged at confluencies between 2 and 5 × 105 cells/ml. All cell lines were routinely tested for
mycoplasma contamination and confirmed negative.
Cell viability studies
To account for different growth rates, cells were seeded in black 96-well plates at densities that provided 80%–
90% confluency after 24 h; KG1a cells (1.5 × 104 cells/well), HeLa (8 × 103 cells/well), MCF-7 (2.5 × 103 cells/
well), MDA-MB-231 (2 × 103 cells/well), and A431 (2 × 103 cells/well) in a total volume of 100 μl. After a
minimum of 24 h, cells were treated with peptides in CM for 24 h. Viability studies were conducted using the
CellTiter-Blue® assay where cells were incubated with 100 ml peptide in CM for 20 h and additionally for 4 h
with 20 ml of CellTiter-Blue® reagent added prior to measurements. Samples were read on a FLUOstar Optima
fluorescent plate reader (Ex. 584 nm, Em. 612 nm) and viability determined after background subtraction by
comparison to a vehicle control.
Determination of EGFR levels in cancer cell lines
For adherent cell lines (HeLa, A431, MCF-7, and MDA-MB-231), cells were grown to ∼70% confluency in
T-75 tissue culture flasks. The medium was aspirated, and the cells were washed three times with PBS. Ice-cold
Table 1 Peptides and proteins used in this study
Sequence
Peptides
L-EJP18 Ac-LFMRRRHIVRKRTLRRLL-NH2
D-EJP18 Ac-lfmrrrhivrkrtlrrll-NH2
Rh-L-EJP18 Rh-LFMRRRHIVRKRTLRRLL-NH2
Rh-D-EJP18 Rh-lfmrrrhivrkrtlrrll-NH2
L-R8 Ac-RRRRRRRR-NH2
Rh-L-R8 Rh-RRRRRRRR-NH2
r8-PAD Ac-rrrrrrrrGGklaklakklaklakGC-NH2
Proteins
eGFP-R8 His6-eGFP-RRRRRRRR
eGFP-EJP18 His6-eGFP-LFMRRRHIVRKRTLRRLL
eGFP His6-eGFP
Capital letters represent L amino acids, the lower case represents
D amino acids, Rh, tetramethylrhodamine; Ac, acyl; NH2, amide
and italics eGFP represent full length enhanced green fluorescent
protein.
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lysis buffer 0.5 ml (50 mM NaCl, 50 mM Tris base pH 8.0, 1% Nonidet p-40 [Sigma–Aldrich, Gillingham, U.
K.] plus cOmplete Mini protease inhibitors [Roche, Burgess Hill, U.K.]) was added on ice and the cells were
scraped from the flask surface. The flask content was transferred to an Eppendorf tube and kept on ice for 5–
15 min, then centrifuged (13 800×g, 4°C) for 15 min, prior to removing the supernatant to a clean Eppendorf
tube. For the non-adherent KG1a cells, the total volume of a T-75 flask was transferred to a 15 ml centrifuge
tube, centrifuged at 900×g for 2 min and then resuspended in 5 ml fresh CM. A volume containing 1 × 106
cells was pelleted by centrifugation at 900×g and resuspended in PBS, washed again in PBS before resuspending
the pellet in ice-cold lysis buffer (620 μl). After 5–15 min, the sample was centrifuged (13 800×g, 4°C) and the
supernatant was harvested. For all cell lines, following lysate collection and protein quantification via the BCA
assay (Fisher Scientific), 20 μg of protein was loaded and run (100 V, 60 min) on a 10% precast gel (Bio-Rad).
Proteins were transferred to polyvinylidene fluoride membranes (Immobilon-P transfer membrane, Fisher
Scientific) and EGFR was detected via immunoblotting (anti-EGFR Ab diluted 1 : 1000 in 2% milk/PBS/0.2%
Tween [Sigma–Aldrich] and incubated overnight). Samples were washed 3× for 5 min in PBS/0.2% Tween and
incubated with the secondary antibody (1 : 1000 in 2% milk/PBS/0.2% Tween), after further washing of 3× for 5
min in PBS/0.2% Tween, membranes were incubated with Clarity ECL reagent and luminescence detected
using a ChemiDoc system (Bio-Rad).
Cell morphology studies
HeLa cells, MDA-MB-231, and A431 cells were seeded in imaging dishes (2.5 × 105, 1.8 × 105, and 2.5 × 105
cells per dish, respectively) and allowed to adhere overnight. Just prior to experimentation, the cells were
washed three times with serum-free media (SFM). In addition, 5 × 105 KG1a cells were collected in an
Eppendorf tube and centrifuged (400×g, 3 min) before being resuspended in SFM and transferred to an
MatTek imaging dish (Ashland, MA, U.S.A.). Peptide solutions (L-EJP18 or D-EJP18 in a final concentration
of 20 mM in 200 ml SFM containing 1 ml DRAQ7™) were then added to the cells. Cells were kept on a humidi-
fied stage (5% CO2, 37°C) and imaged by confocal microscopy using the 633 nm laser with a 63× 1.4NA
objective. Images were acquired at 30 s intervals over 1 h. Images were processed using ImageJ software [26].
Confocal microscopy of Rh-CPP, eGFP-CPP, and CPP : BSA complexes
HeLa cells and MDA-MB-231 cells were seeded at a density of 1.8 × 105 cells per imaging dish and allowed to
adhere overnight under tissue culture conditions. The next day, where applicable, cell lysosomes were labelled
by incubating the cells with 100 mg/ml 10 kDa dextran-Alexa488 (Dex488) or 10 kDa dextran-Alexa647
(Dex647, both Fisher Scientific) for 2 h in CM under tissue culture conditions. Subsequently, cells were washed
three times with CM and incubated for 12–14 h to chase the dextran into the lysosomes [27,28].
On the day of the experiment, cells were washed with SFM and incubated with either Rh-CPP, eGFP-CPP,
or CPP : BSA complexes in SFM for 1 h, 37°C 5% CO2. Complexes were formed containing 8 mM CPP and
240 nM BSA-Alexa647 (BSA647) in nuclease-free distilled water for 30 min at room temperature following a
protocol based on Sayers et al. [29]. Following this the complexes were diluted 1 : 3 with SFM giving final CPP
and BSA concentrations of 2 mM and 60 nM, respectively, and incubated with the cells for 1 h under tissue
culture conditions. For pulse-chase peptide experiments in cells (Figure 6), lysosome labelled cells were washed
in CM and re-incubated for 1 h before imaging. Where low-temperature experiments were performed, cells
were pre-chilled on ice (4°C) for 15 min before washing and incubating with pre-chilled Rh-CPP in SFM for
1 h. Here, cells were washed and imaged in pre-chilled imaging medium.
After the incubation period, cells were washed with imaging medium (phenol red free DMEM supplemented
with 25 mM HEPES pH 7.4 and 10% FBS) and finally imaged in imaging medium containing Hoechst 33342
(10 mg/ml) and analysed on a Leica SP5 confocal microscope (63× 1.4 N.A. objective using 405 nm, 488 nm or
543 nm and 633 nm lasers with a 95.5 μm pinhole, pixel size is 283 nm, using Leica Type F immersion oil).
Sequential scanning was used to separate overlapping emission profiles. All cell imaging was performed in live
cells at 37°C, 5% CO2, 90% humidity over the course of the experiment apart from low-temperature uptake
studies that were imaged in ice-cold imaging medium.
Flow cytometry analysis of Rh-CPP, eGFP-CPP, and CPP : BSA complexes
HeLa cells and MDA-MB-231 cells were seeded at a density of 1 × 105 cells per well in 12-well plates so that
they were 80%–90% confluent on the day of the experiment. On the day of the experiment, the medium was
aspirated, and the cells were washed with SFM and then incubated under tissue culture conditions for 1 h with
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test compounds (L-EJP18, D-EJP18, or L-R8 at 1–5 mM in SFM) either as Rh-labelled conjugates, or as
BSA647 complexes prepared as above. The experiment was repeated at 4 °C for the Rh-labelled conjugates at
2 mM. Following 1 h of exposure, the test compounds were removed, and cells were washed with ice-cold PBS
and then detached with trypsin at 37°C. The trypsinisation was terminated by the addition of ice-cold CM, and
the cell suspensions were collected in Eppendorf tubes and centrifuged (270×g, 4°C, 4 min). The supernatant
was removed and the cells were washed with ice-cold heparin Sulfate (Sigma–Aldrich, diluted 20 mg/ml in PBS)
before being centrifuged again under the same conditions and resuspended in ice-cold CM. Hereafter, the cells
were kept on ice before analysis on a Gallios flow cytometer (Beckman Coulter, Fullerton, CA, U.S.A.). At least
5000 viable cells were counted, using gating for front- and side scattering. Rh-labelled EJP18 and BSA647 were
detected using red and far-red filters.
Data analysis
The IC50 values for EJP18 towards each cell line were calculated using GraphPad Prism (GraphPad Software,
La Jolla, CA, U.S.A.) and the Hill equation (shown below), as described by Birch et al. [30].
Relative viability(%) ¼ Top Bottom
1þ 10(LogIC50Log[CPP]) Hill slope
To prevent erroneous calculations as a result of autophagocytosis, the top of the curve was constrained at 100%
viability.
Data were compared with a one-way ANOVA combined with a Tukey’s multiple comparison analysis using
GraphPad Prism.
Results
Both L- and D-forms of the EJP18 peptide were initially tested against four cancer cell lines from a range of
tissues to determine the effects of the L (Figure 1A) and D (Figure 1B) forms on cell viability (Table 2). Both
showed little toxicity below 10 μM when incubated with cells for 24 h and above this concentration, the differ-
ent cell lines had varied sensitivities. In the skin epithelial A431 cell line only limited toxicity was observed to
the L enantiomer (IC50 > 100 mM) and moderate toxicity against the D enantiomer (IC50∼ 22 mM). In contrast,
the acute myeloid leukaemia cell line KG1a showed the highest susceptibility to L-EJP18 with toxicity only
marginally higher when exposed to the D enantiomer (IC50 20 versus 15 mM). The cervical epithelial HeLa line
showed a much higher level of sensitivity to the D over the L form of the peptide giving IC50 values of 63 mM
versus 12 mM, respectively. Mammary epithelial line MDA-MB-231 proved the most resistant to toxicity from
D-EJP18, with an IC50 approximately half the value than when incubated with L-EJP18.
To determine if there was any relationship between the toxicity of our peptide and EGFR expression levels,
protein normalised EGFR expression was tested by Western blot. Both A431 and MDA-MB-231 cell lines
showed high EGFR expression while HeLa and KG1a, respectively, produced low and undetectable levels of this
protein (Figure 1C). This is in agreement with mRNA expression profiles from ‘The Human Protein Atlas’ and
the ‘Cancer Cell Line Encyclopaedia’ (CCLE) for HeLa, MDA-MB-231, and A431 cells [31,32], and no EGFR
data could be identified for KG1a cells. The high EGFR expressing cell line, A431, had the lowest L-EJP18 tox-
icity and the lowest EGFR expressor, KG1a, had the highest L-EJP18 toxicity. MDA-MB-231 and HeLa cells
have similar toxicity profiles and D-EJP18, showed no correlation between EGFR expression and toxicity.
Using live cell time lapse confocal microscopy, we have previously shown that some cationic toxic peptides
very rapidly cause large protrusions to emanate from the plasma membrane immediately prior to evidence of
membrane damage and porosity to dyes such as propidium iodide [7,21]. Focusing on a high EGFR expressor
(MDA-MB-231), a low expressor (HeLa) and the previously tested suspension cell line KG1a, we evaluated
their immediate responses to 20 mM of both EJP18 enantiomers in comparison with r8-PAD
(rrrrrrrrGGklaklakklaklakGC) that we previously showed to be extremely plasma membrane-active and toxic at
20 mM [7]. Cells incubated with the peptides were imaged by time lapse microscopy every 30 s for 1 h in the
presence of DRAQ7, a marker for membrane permeability, and the results are shown as movies M1–M12
(Supplementary Information); the 1 h time point is shown in Figure 2. The movies clearly demonstrate very
rapid high plasma membrane activity of r8-PAD producing large blebs on the surface of all three cell lines
before showing the first signs of porosity to DRAQ7 between 5 and 10 min; within 1 h all cells were DRAQ7
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positive. KG1a cells incubated with the EJP18 enantiomers also showed rapid and extensive ‘blebbing’ of the
plasma membrane with D-EJP18 (Supplementary Movie MS11) producing blebs on the surface within 25 min
compared with 40 min for L-EJP18 (Supplementary Movie MS10). Despite this, the cells were not strongly
positive for DRAQ7 with weak dye signals identified in a minority of cells after 1 h. MDA-MB-231 cells
showed minor membrane disturbance when incubated with both enantiomers and remained DRAQ7 negative
throughout the 1 h period (Supplementary Movies MS6 and MS7). Membrane protrusions were visible for
both enantiomers of peptide when incubated with HeLa cells (Supplementary Movies MS2 and MS3), and
those incubated with D-EJP18 showed evidence of membrane porosity. Overall, these time lapse experiments
reflect the data seen in the 24 h viability assays (Figure 1) and noticeable is that the HeLa cell line is much
more susceptible to the D enantiomer over the L enantiomer.
As the peptides clearly showed plasma membrane activity, we analysed their ability to carry a fluorescent
model small molecule ([tetramethyl]rhodamine, Rh) and protein cargos (albumin and eGFP) to MDA-MB-231
Figure 1. Viability and EGFR expression of cell lines incubated with L- and D-EJP18.
Viability of HeLa cells (red), MDA-MB-231 cells (yellow), KG1a cells (green), and A431 (purple) following incubation with
L-EJP18 (A) or D-EJP18 (B) for 24 h in CM. The dotted line depicts 50% viable cells. Mean ± SEM, n = 3, N = 3. (C)
Representative Western blot showing the relative expression of EGFR in the four cell lines normalised by total protein
concentration.
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and HeLa cells at 1–5 mM. Cells were incubated with L- and D-Rh-EJP18 for 1 h and analysed by live cell con-
focal microscopy and flow cytometry, along with Rh-L-R8 representing a very well-characterised CPP [33,34].
At 2 mM all three peptides were visible in vesicular structures in both cell lines (Figure 3A,B). The intensity of
these vesicles was most prominent in HeLa incubated with Rh-L-EJP18. Fluorescence from both Rh-EJP18
enantiomers and Rh-L-R8 was punctate-scattered in the cytoplasm with some enrichment in a juxtanuclear
region; similar subcellular distribution of fluorescence was observed in MDA-MB-231 cells. For both these cell
lines, there was little colocalisation of either enantiomer with Transferrin-Alexa488 (a marker for early and
recycling endosomes) following a 1 h pulse (Supplementary Figure S4).
Incubating cells on ice with 2 mM Rh-peptides (Table 1) for 1 h produced no visible fluorescence (data not
shown). Increasing peptide concentration to 10 mM showed little internalised fluorescence of either Rh-EJP18
peptide with a minority of cells showing small plasma membrane bound aggregates (Supplementary Figure S5).
As seen previously using L-R8-Alexa488 [33], Rh-L-R8 gives cytosolic and nuclear labelling when incubated at
high concentrations (here 10 mM) at 4°C in serum-free medium. This highlights that uptake of EJP18 peptides
can only occur in the presence of energy and unlike L-R8 the sequence cannot directly translocate through the
plasma membrane at 4°C.
We then used flow cytometry to quantify peptide uptake and at 1 mM, in both cell lines, cell-associated
fluorescence was significantly higher (P < 0.001) for Rh-D-EJP18 compared with Rh-L-EJP18 or Rh-L-R8 for
Table 2 IC50 cell viability values for the four cell lines tested
Cell line L-EJP18 IC50 (mM) D-EJP18 IC50 (mM)
HeLa 63.7 ± 7.9 12.2 ± 1.3
MDA-MB-231 63.0 ± 20.3 28.9 ± 2.5
KG1a 20.2 ± 1.5 15.8 ± 2.9
A431 >100 22.6 ± 8.2
Values calculated from viability curves in Figure 1. Values represent the mean
of the repeats ± SEM, n = 3, N = 3.
Figure 2. Morphological changes in KG1a, HeLa, and MDA-MB-231 cells incubated with L- and D-EJP18.
Cells were incubated with/without 20 mM CPP for 1 h in SFM in the presence of DRAQ7 (red). Representative images are from
two identical experiments in different passages. Scale bars = 20 mm. For 1-h time lapse movies see Supplementary Movies
MS1–MS12.
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both cell lines (Figure 3C,D). Morphological effects in cells incubated with higher concentrations of
Rh-D-EJP18 resulted in the majority of cell counts falling outside of the gated region (data not shown) and a
reliable fluorescence intensity reading for these concentrations could not be obtained. Uptake levels were
similar between Rh-L-EJP18 and Rh-L-R8 at 2 and 5 mM (P > 0.05).
Cell-penetrating peptides have been shown to deliver proteins to cells as non-covalent complexes or
CPP-fusions expressed in E. coli and purified [25,35–38]. Enhanced green fluorescent protein (eGFP) was
selected as a model protein and synthesised in frame with EJP18 and purified as an eGFP-EJP18 conjugate. Its
cellular uptake was analysed by microscopy in comparison with eGFP-R8 in HeLa (Figure 4A) and
MDA-MB-231 cells (Figure 4B). For both cell lines, there was appreciably higher visible cell-associated fluores-
cence after incubation with 2 mM eGFP-EJP18 than eGFP-R8, with eGFP alone showing no observed fluores-
cence under these microscopy settings. While cells incubated with Rh-EJP18 showed only punctate endosomal
fluorescence after 1 h, eGFP-EJP18 was present as punctate vesicular fluorescence but also labelled the plasma
membrane. Labelling the plasma membrane of both cell lines showed, in addition to endocytic structures,
aggregation of the protein–peptide conjugate at or very close to the plasma membrane after 1 h of incubation
(Supplementary Figure S6). Brightness enhancing the eGFP-R8 images incubated with both cell lines allowed
us to more easily determine these subcellular localisations (Supplementary Figure S7). In both cell lines,
eGFP-R8 was located to small scattered vesicles.
Figure 3. Uptake of Rh-EJP18 in HeLa and MDA-MB-231 cells.
HeLa (A) and MDA-MB-231 (B) cells were incubated with 2 mM Rh-labelled L-EJP18, D-EJP18, or L-R8 in SFM for 1 h prior to
washing and imaging. Scale bars = 20 mm. Relative uptake of Rh-L-EJP18, Rh-D-EJP18, and Rh-L-R8 into HeLa (C) and
MDA-MB-231 (D) cells. Cells were treated with test solution (1–5 mM in SFM) for 1 h at tissue culture conditions and
subsequently analysed by flow cytometry. Fluorescence values are a mean of the mean geometric mean from three
independent experiments performed in triplicate. Mean ± SEM, n = 3, N = 3. For example, histograms see Supplementary
Figure S3, for additional comparative statistics from the ANOVA see Supplementary Tables S1 and S2.
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To assess the capacity of EJP18 to internalise protein as non-covalent CPP : protein complexes, the peptides
were mixed with fluorescent BSA647 at a molar ratio of 100 to 3 before adding to cells as CPP : BSA647. L-R8
and L-EJP18 failed to enhance BSA647 internalisation above background levels in either HeLa or
MDA-MB-231 cells at any of the tested concentrations (Figure 5). However, D-EJP18 proved successful in
internalising significant amounts of this protein at 2 mM localising to scattered vesicles in a similar pattern
seen with the Rh-EJP18 peptides. This high uptake was mirrored by flow cytometry where, at the lowest con-
centration, D-EJP18 was able to internalise significantly higher amounts of BSA647 than the other peptides in
both cell lines and values for D-EJP18 : BSA647 exceeded values obtained when the other peptides were at five
times higher concentrations. It should be noted that, similar to results seen for the rhodamine constructs,
D-EJP18 : BSA647 produced morphological changes at 2 and 5 mM that shifted HeLa and MDA-MB-231
outside of the gated region after preparation for flow cytometry. In Hela cells, there were no significant differ-
ences in the uptake of BSA647 by either L-EJP18, L-R8 or without peptide complexation. In MDA-MB-231
cells, 1 mM D-EJP18 internalised significantly more BSA than the L-enantiomer; and notably, in this cell line
L-R8 outperformed L-EJP18 at low concentrations (1 or 2 mM), however, at 5 mM they were statistically
equivalent.
To further explore the endocytosis of EJP18-cargo, we investigated whether, once internalised, they trafficked
by endocytosis to lysosomes. For these experiments, lysosomes were labelled via a short pulse and overnight
chase with fluorescent dextran that is known to traffic to these organelles via Rab7a labelled late endosomes
[27]. This then allowed for subsequent analysis of the intracellular delivery of the EJP18 conjugates to these
organelles in HeLa and MDA-MB-231 after a short 1 h ‘pulse’ incubation (Figure 6). HeLa incubated with
Figure 4. Cell uptake of eGFP by EJP18 and L-R8.
HeLa (A) and MDA-MB-231 (B) cells were incubated with 2 mM eGFP-EJP18, eGFP-R8, or eGFP in SFM for 1 h prior to
washing and imaging by confocal microscopy. Scale bar = 20 mm.
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Rh-labelled D- or L-EJP18 showed a moderate level of colocalisation between with the probe and lysosomes. In
both cases, fluorescent peptide was scattered throughout the cell. A similar level of colocalisation and distribu-
tion was seen with EJP18 : BSA647 complexes. In contrast, MDA-MB-231 incubated with either Rh-EJP18 or
EJP18 : BSA647 showed low levels of colocalisation indicating that either the peptide/protein complexes
Figure 5. Cell uptake of peptide-BSA complexes in cells.
Complexes of CPP and BSA were formed by mixing 8 mM L-EJP18, D-EJP18, or L-R8 (unlabelled) with 240 nM BSA-Alexa647
(molar ratio CPP : BSA 100 : 3) in distilled water for 30 min at room temperature. Complexes were subsequently diluted one part
in four in SFM, to produce final peptide and protein concentrations of 2 mM and 60 nM, respectively, and incubated with (A)
HeLa or (B) MDA-MB-231 cells for 1 h prior to washing and imaging. Scale bars = 20 mm. Relative uptake of L-EJP18,
D-EJP18, and L-R8 complexed with BSA-Alexa647 into (C) HeLa and (D) MDA-MB-231 cells. Cells were treated with tested
peptides (1–5 mM in SFM) for 1 h at tissue culture conditions and subsequently analysed by flow cytometry. Fluorescence
values are a mean of the mean geometric mean from three independent experiments performed in triplicate. Mean ± SEM, n =
3, N = 3. For example, histograms see Supplementary Figure S8, for additional comparative statistics from the ANOVA see
Supplementary Tables S3 and S4.
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trafficked differently in this cell line, or the overall rate of trafficking to the lysosome was much slower.
Interestingly, both the Rh-EJP18 and EJP18 : BSA complexes seemed to localise to a similar juxtanuclear region
containing dextran labelled lysosomes; that in this cell line also harbours EEA1-labelled early endosomes and
LAMP-1-labelled lysosomes [39,40]. Both HeLa and MDA-MB-231 incubated with eGFP-EJP18 showed no
colocalisation with lysosomes. In both cases, fluorescence was limited to puncta at the periphery of the cell
indicating that further internalisation of this fraction to the lysosomal system is relatively slow.
Figure 6. Differential rates of endocytic traffic to lysosomes for small molecule or protein cargo delivered by EJP18.
HeLa (A) and MDA-MB-231 (B) cells, with the lysosomes pre-loaded with fluorescent dextran (magenta), were incubated with
2 mM rhodamine labelled L- or D-EJP18, 2 mM L- or D-EJP18 complexed with 60 nM BSA-Alexa 647 or 2 mM eGFP-EJP18 (all
in green) in SFM for 1 h. Cells were chased by incubating in CM for a further 1 h before imaging in the presence of Hoechst
33342. Scale bar = 20 mm. Arrows indicate colocalised cargo and lysosomal dextran, solid arrows indicate non-colocalised
cargo and hollow arrow heads indicate non-colocalised lysosomal dextran. Image intensities have been adjusted so that
differences in colocalisation can be more evenly compared. All images are single sections. Enlarged overlays can be found as
Supplementary Figure S9.
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Discussion
Our time lapse microscopy experiments clearly highlighted the capacity of both EJP18 enantiomers to affect
plasma membrane integrity at concentrations higher than 10 mM. Based on this and the collected viability data
together with EGFR expression analysis, it is very unlikely that EJP18 toxicity is linked to the expression of this
receptor. This suggests that the peptide has an alternative mechanism for inducing cell toxicity that most prob-
ably lies at the level of the plasma membrane. EGFR levels were predictive of the toxicity of another EGFR JM
derived peptide conjugated to Tat49–58 (TE-64562) [17]. Cell lines that expressed moderate to high EGFR were
more susceptible to TE-64562 and there was no toxicity (up to 100 mM) or delivery capacity associated with
the JM sequence alone (RRRHIVRKRTLRRLLQER). Noted is that this sequence, like that of EJP18, is also
composed of 18 residues, however, at the N- and C-terminus lie cationic residues. This strongly supports our
initial hypothesis that hydrophobic termini aid membrane interaction. However, it is very difficult to refute the
possibility that the JM cargo peptide in TE-64562 had a significant influence on the capacity of Tat49–58 to
enter cells. In support of this finding, a very short threonine phosphorylated peptide termed T654 from this JM
of EGFR (Ac-RKRTPLRRLK-fluorescein) entered cells and inhibited irradiation-induced nuclear localisation of
EGFR [41]. However, uptake was monitored after 16 h and it is very difficult to determine its subcellular local-
isation. More recently a peptide consisting of a pH-dependent membrane spanning sequence (pHLIP) in frame
with a very short EGFR JM sequence 654-TLRRLLQ-660 was shown to inhibit EGRF dimerisation, inhibit cell
migration and induce cytotoxicity and downstream effects [42]. It would be interesting to determine whether
this shorter peptide influences the membrane spanning capacity of pHLIP or whether EJP18 could also be
active in this way attached to pHLIP to give higher selectivity. While there were no links between EGFR expres-
sion and EJP18 induced toxicity, the peptide may be having some effects on receptor dimerisation and/or acti-
vation, similar to those seen with TE64562, T654, and pHLIP-JMA [17,41,42]. To interact with the EGFR JM
domain, as initially predicted, would require crossing the plasma membrane to reach the target. While there
was little evidence of cytosolic delivery, we cannot refute the possibility that a very low fraction, beyond the
limit of detection of our assay, was able to perform this feat.
The general increased toxicity of the D- versus L-EJP18 is likely to be due to degradation of the latter by pro-
teases that are known to have significant effects on CPP translocation activities [43]. These may be present in
the serum as a purchased product or may be released from cells during the incubation stages. Thus, the effect-
ive concentration of D- versus L- forms are maintained for a longer period to mediate effects [44]. This is cor-
roborated by similar studies on the exposure of penetratin to Caco-2 cells, in which intact D-penetratin elicited
more detrimental effects than the corresponding L form [45].
The mechanism by which these peptides cause such profound membrane disruption is unknown and also
unknown is whether pores are initially formed before physical blebbing and DRAQ7 staining can be observed.
These observations are similar to the effects on mammalian cells of equivalent concentrations of the extensively
studied pore forming bee venom toxins melittin and mastoparan [46,47]. Interestingly, four of the five cationic
residues on the 26 residue melittin (GIGAVLKVLTTGLPALISWIKRKRQQ) are localised together at the
C-terminus whilst two of the three same residues in mastoparan also are localised at the C-terminus
(INLKALAALAKKIL). Both these peptides have toxic effects on mammalian and eukaryotic cells, thought to
be induced by the formation of pores in membranes [48]; other membrane interacting effects have also been
noted [49]. It remains to be determined whether the interaction of these peptides with membranes is similar to
that of EJP18 with its cationic residues spaced throughout the sequence, flanked by two hydrophobic residues
at each end. The presence of punctate spots on (or adjacent to) the plasma membrane suggests the occurrence
of oligomerisation. It has been noted that peptide dimers of the amphiphilic peptide, LK-3, induced further
oligomerisation and the burying of their hydrophobic motifs in the plasma membrane to aid internalisation [50].
Overall EJP18 managed to deliver a small molecule fluorophore and macromolecular protein cargoes cova-
lently attached via a peptide bond or as non-covalent protein : peptide complexes. There is still significant inter-
est in delivering proteins to cells by CPPs to mediate a biological response interest or for delivery across a
biological barrier [37,51]. The eGFP-EJP18 protein conjugate appeared to aggregate on the plasma membrane
of the cell. However, further scrutiny clearly identified endocytic uptake as well as association with different
regions of the plasma membrane. However, when the peptide was complexed with BSA there was clear signs
that endocytosis was occurring and this was marked by very different eGFP-EJP18 and EJP18 : BSA localisation
after a 1 h pulse — 1 h chase. Interestingly, both the Rh-EJP18 and EJP18 : BSA complexes seemed to localise
to a similar juxtanuclear region containing dextran labelled lysosomes; that in this cell line also harbours
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EEA1-labelled early endosomes and LAMP-1-labelled lysosomes [39,40]. Our initial experiments with the
Rh-conjugated peptides and transferrin suggests little or no involvement of clathrin-mediated endocytosis as an
uptake process and this warrants further analysis. For all studies presented here, there was little evidence that
either L- or D-EJP18 was able to promote the delivery of fluorophore or protein to the cytosol of cells but the
small fraction that may escape through the plasma or endosomal membrane is extremely difficult to detect by
fluorescence microscopy.
The EJP18 sequence was derived from the JM of EGFR, a member of the ErbB family of signalling receptors
that, in humans, form the larger 58-member receptor tyrosine kinase family [52]. Within the JM region, there
are some interesting and notable sequence conservation that is predicted to influence function through interac-
tions with negatively charged lipids [52]. Of interest is the fact that the JM regions of many RTKs are rich in
positively charged residues suggesting that other potential CPPs may be hidden within this family of proteins
(Table 3). This hypothesis remains to be tested.
Table 3 Juxtamembrane and transmembrane (TM) peptide sequences of 58 human RTKs
Class RTK
Upstream
TM (5 aa)
Juxtamembrane sequence
(20 aa) Class RTK
Upstream
TM (5 aa)
Juxtamembrane sequence
(20 aa)
I EGFR IGLFM RRRHIVRKRTLRRLLQEREL XI Tyro3 LALIL LRKRRKETRFGQAFDSVMAR
I ErbB2 FGILI KRRQQKIRKYTMRRLLQETE XI Mer SLAIR KRVQETKFGNAFTEEDSELV
I ErbB3 GGTFL YWRGRRIQNKRAMRRYLERG XII TIE1 LLTLV CIRRSCLHRRRTFTYQSGSG
I ErbB4 FAVYV RRKSIKKKRALRRFLETELV XII TIE2 AFLII LQLKRANVQRRMAQAFQNVR
II InsR IYLFL RKRQPDGPLGPLYASSNPEY XIII EphA1 GILVF RSRRAQRQRQQRQRDRATDV
II IGF1R LYVFH RKRNNSRLGNGVLYASVNPE XIII EphA2 VGFFI HRRRKNQRARQSPEDVYFSK
II IRR ALGFF YGKKRNRTLYASVNPEYFSA XIII EphA3 YVLIG RFCGYKSKHGADEKRLHFGN
III PDGFRα LVVIW KQKPRYEIRWRVIESISPDG XIII EphA4 AAFVI SRRRSKYSKAKQEADEEKHL
III PDGFRβ LIILI MLWQKKPRYEIRWKVIESVS XIII EphA5 IGVLL SGSCCECGCGRASSLCAVAH
III KIT MILTY KYLQKPMYEVQWKVVEEING XIII EphA6 LFFLI TGRCQWYIKAKMKSEEKRRN
III CSF1R LLLLY KYKQKPKYQVRWKIIESYEG XIII EphA7 MVFGF IIGRRHCGYSKADQEGDEEL
III FLT3 TLLIC HKYKKQFRYESQLQMVQVTG XIII EphA8 LLLIC KKRHCGYSKAFQDSDEEKMH
IV VEGFR1 LTLFI RKMKRSSSEIKTDYLSIIMD XIII EphA10 VMSVL AIWRRPCSYGKGGGDAHDEE
IV VEGFR2 LLVII LRTVKRANGGELKTGYLSIV XIII EphB1 ISIVC SRKRAYSKEAVYSDKLQHYS
IV VEGFR3 LLLLI FCNMRRPAHADIKTGYLSII XIII EphB2 VIAIV CNRRGFERADSEYTDKLQHY
V FGFR1 SVIVY KMKSGTKKSDFHSQMAVHKL XIII EphB3 VIAIV CLRKQRHGSDSEYTEKLQQY
V FGFR2 TVILC RMKNTTKKPDFSSQPAVHKL XIII EphB4 IVVAV LCLRKQSNGREAEYSDKHGQ
V FGFR3 AVTLC RLRSPPKKGLGSPTVHKISR XIII EphB6 AITVL AVVFQRKRRGTGYTEQLQQY
V FGFR4 LAGLY RGQALHGRHPRPPATVQKLS XIV Ret SAFCI HCYHKFAHKPPISSAEMTFR
VI PTK7 GLMFY CKKRCKAKRLQKQPEGEEPE XV RYK AIILA VLHLHSMKRIELDDSISASS
VII NTRK1 LLLVL NKCGRRNKFGINRPAVLAPE XVI DDR1 IALML WRLHWRRLLSKAERRVLEEE
VII NTRK2 MLFLL LARHSKFGMKGPASVISNDD XVI DDR2 VIILW RQFWQKMLEKASRRMLDDEM
VII NTRK3 LFVMI NKYGRRSKFGMKGPVAVISG XVII ROS LTFVW HRRLKNQKSAKEGVTVLINE
VIII ROR1 FFICV CRNNQKSSSAPVQRQPKHVR XVIII LMTK1 LMLAC LCCKKGGIGFKEFENAEGDE
VIII ROR2 CLFFL VCMCRNKQKASASTPQRRQL XVIII LMTK2 IVLIA NCVSCCKDPEIDFKEFEDNF
IX MuSK ITTLY CCRRRKQWKNKKRESAAVTL XVIII LMTK3 LLTCL CCKRGDVGFKEFENPEGEDC
X MET FFLWL KKRKQIKDLGSELVRYDARV XIX LTK VLILV KQKKWQGLQEMRLPSPELEL
X Ron TALVF SYWWRRKQLVLPPNLNDLAS XIX ALK IMIVY RRKHQELQAMQMELQSPEYK
XI Axl ALFLV HRRKKETRYGEVFEPTVERG XX STYK1 GVILW LFIREQRTQQQRSGPQGIAP
Positively charged amino acids in green, negatively charged amino acids in red, bold represents phosphorylated or putative phosphorylated amino
acids (data collected from Uniprot).
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Conclusions
Peptides such as melittin and mastoparan have been extensively studied as models of protein–membrane inter-
action and EJP18 can be seen as a new member of this family. As a natural membrane interacting region
within EGFR, this sequence interacts with phosphatidylinositol 4,5 bisphosphate (PIP2) and other phospholi-
pids on the inner leaf of the membrane [53]. Further information on EJP18 membrane interaction may be
gleaned from studies with artificial membranes containing PIP2 that has been shown to mediate the oligomer-
isation of antimicrobial defensin peptides leading to cytotoxicity [54,55]. At concentrations greater than 10 mM
L- and D-EJP18 are highly membrane-active and differentially toxic to the cell lines studied here. There
remains significant interest in cytotoxic peptides and their derivatives as anti-cancer agents and delivery vectors
[56] and EJP18 may in the future fall into this category. A clear overlap between sequences of cell-penetrating
and antimicrobial peptides has been noted [57,58] and it remains to be determined whether our sequence also
has activity against prokaryotes and fungi. At low concentrations, the EJP18 sequences were at least as effective
as L-R8 in delivering a fluorophore and proteins to cells thus allowing for their classification as novel CPP.
This merits further analysis of whether their translocation activities can be exploited to deliver a therapeutic
cargo across a biological barrier to mediate a physiological response.
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